Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2023.4889 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Keshavamurthy Vinay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Acitretin, Lichen Planus, Oral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Symptomatic oral lichen planus (OLP) can be challenging to treat.
Objective
To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP. Design, Setting, and Participants This monocentric, investigator-initiated, placebo-controlled, investigator- and patient-blinded randomized clinical trial was conducted from December 2018 to June 2020 at the Postgraduate Institute of Medical Education and Research, a tertiary referral center in Chandigarh, India. Sixty-four patients 18 years or older with symptomatic OLP were recruited by consecutive sampling. Data were analyzed from July to December 2020.
Intervention
The patients were randomized to receive either a combination of oral acitretin (25-35 mg/d) and TAC (treatment group) or TAC in combination with placebo (placebo group) for 28 weeks, with an additional 8 weeks of treatment-free follow-up after the end of treatment (36 weeks of total study duration). Main Outcomes and Measures The disease severity and treatment response were assessed using Oral Disease Severity Score (ODSS), Oral Health Impact Profile 14 (OHIP-14), and visual analog scale (VAS). The primary aim was to assess the number of patients achieving ODSS-75 (75% reduction in ODSS compared with baseline) in both groups at 28 weeks and at the end of 36 weeks.
Results
Among 64 patients, 31 in the treatment group and 30 in the placebo group completed the study (mean [SD] age, 50.6 [15.2] years vs 49.2 [14.4] years; male-female ratio, 13:19 vs 16:16). Baseline ODSS, visual analog scale, and Oral Health Impact Profile 14 scores were comparable in both groups. In the intention-to-treat analysis, there was a statistically significant higher number of patients achieving 75% or higher reduction in ODSS in the treatment group compared with the placebo group at the end of 28 weeks (28 [88%] vs 15 [47%], a 41 [95% CI, 20-61] percentage point difference between groups; P < .001; Cramér V = 0.47) and 36 weeks (27 [84%] vs 13 [41%], a 43 [95% CI, 23-67] percentage point difference between groups; P < .001; Cramér V = 0.47). Relapses during the posttreatment follow-up of 8 weeks were low among patients in both treatment and placebo groups (1 [3%] vs 2 [6%], a 3 [95% CI, −13 to 7] percentage point difference between groups; P > .99; Cramér V = 0.07). Conclusion and Relevance In this randomized clinical trial, the combination of oral acitretin and TAC was more effective than TAC monotherapy in patients with symptomatic OLP. Trial Registration Clinical Trial Registry of India Identifier: CTRI/2018/11/016448
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
- Centro Studi GISED, Bergamo, Italy.
Zitieren
APA
Vinay, K., Kumar, S., Dev, A., Cazzaniga, S., Borradori, L., Thakur, V., & Dogra, S. (2024). Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.4889
Vancouver
Vinay K, Kumar S, Dev A, Cazzaniga S, Borradori L, Thakur V, et al. Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2023.4889
BibTeX
@article{Vinay2024,
author = {Vinay, Keshavamurthy and Kumar, Sheetanshu and Dev, Anubha and Cazzaniga, Simone and Borradori, Luca and Thakur, Vishal and Dogra, Sunil},
title = {Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2023.4889}
}
EUVIMED